Edison Lithium Corp. has signed an option agreement with Globex Mining to earn a 100% interest in the Joutel North-West gold property and the Gagné gold-copper property in Quebec, subject to a 3% gross metal royalty retained by Globex. The transaction requires final approval from the TSX Venture Exchange and Edison is working to meet all conditions. The company recently filed a technical report on the properties, supporting the deal's progress. This acquisition aligns with Edison's strategy to build a portfolio of energy metal assets for the battery industry.
Edison Lithium's update on its proposed acquisition comes as the Basic Materials sector on Pluang showed a breadth of 7 stocks rising and 30 falling out of 38 priced US stocks. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 02, 2026 03:27 WIB: ArcelorMittal SA (MT) was priced at USD 66.74 with a 1-day change of -1.80% and a Pluang order activity of 69% Sell / 31% Buy, Gold Fields Limited (GFI) at USD 36.15 with a -1.70% change and 56% Sell / 44% Buy, and Lithium Americas Corp (LAC) at USD 2.59 with a -1.52% change and 65% Sell / 35% Buy. Typical hold times ranged from 26 to 49 days across these assets.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
